Skip to Content
Søk Menu

Updated Real-World Data Confirm the Effectiveness of Avelumab in First-Line Maintenance Treatment of Advanced Urothelial Carcinoma

Philippe Barthélémy discusses in this MEDtalk from ESMO 2024 the updated results from the AVENANCE trial. They confirm the effectiveness of avelumab first line maintenance in a real-world population.
Philippe Barthélémy

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Interview With Thomas Powles

Maximizing the Tolerability of Enfortumab Vedotin + Pembrolizumab – The Upcoming New Standard Treatment for Advanced Bladder Cancer

/ Thomas Powles
Blåscancer Play the Video 05:55

PD-1 Inhibitors Have Shown Remarkable Efficacy

/ BestPractice Nordic
ESMO24Mag-tarmcancer

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ BestPractice Nordic
ESMO24Mag-tarmcancer

Several Unsettled Questions About Breast Cancer Treatment

/ BestPractice Nordic
BröstcancerESMO24

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ BestPractice Nordic
ESMO24Gynekologisk cancer

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lungcancer

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

/ BestPractice Nordic
ESMO24Gynekologisk cancer

Ten-Year Survival Data from a Groundbreaking Trial for the Treatment of Metastatic Melanoma

/ BestPractice Nordic
ESMO24Melanom

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lungcancer
Back to top